Fundz

Jena Valve Technology Inc reported raising $100 Million in an initial SEC Form D filing, from an offering of $50.2 Million

PRIVATEJan 04, 2022

Amount Raised

$100 Million

$100 Million sold, per SEC Form D (first sale Jan 4, 2022)

Round Type

Venture

IrvineManufacturingInformation TechnologyBiotechnologyHealthcareHealth CareMedical Device

Who else raised in Healthcare and Medical Device around the same time

Companies in the same sectors as JenaValve that raised within 45 days of this round, from Fundz verified event records.

  • Confluent Medical raised an undisclosed amount on February 17, 2022.
  • Levita Magnetics International Corp. raised $20M on February 15, 2022.
  • Avenda Health, Inc. raised $6.4M on February 11, 2022.
  • Talphera, Inc. raised $5.2M on January 24, 2022.
  • Confluent Medical raised an undisclosed amount (Corporate Round) on January 5, 2022.
  • Conavi Medical raised an undisclosed amount (Funding Round) on December 15, 2021.

Who to call at JenaValve, and when

A new round usually means JenaValve is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day JenaValve raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at JenaValve, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at JenaValve. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

JenaValve

Location

Irvine, California, United States

About

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment JenaValve raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJohn K., CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for JenaValve's next move

See what Strategic adds

JenaValve raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.